Scope Issue in Contingent Valuation Studies of the COVID-19 Vaccine: The Case of China

Jianhong Xiao (), Yihui Wu (), Min Wang () and Zegang Ma ()
Additional contact information
Jianhong Xiao: Qingdao University
Yihui Wu: Qingdao University
Min Wang: Qingdao University
Zegang Ma: Qingdao University

Applied Health Economics and Health Policy, 2022, vol. 20, issue 3, No 11, 417-429

Abstract: Abstract Background Assessing the public’s willingness to pay (WTP) for the coronavirus disease 2019 (COVID-19) vaccine by the contingent valuation (CV) method can provide a relevant basis for government pricing. However, the scope issue of the CV method can seriously affect the validity and reliability of the estimation results. Aim To examine whether there are scope issues in respondents’ WTP for the COVID-19 vaccine and to further verify the validity and reliability of the CV estimate results. Method In this study, nine different CV double-bounded dichotomous choices (DBDC) hypothetical COVID-19 vaccine scenarios were designed using an orthogonal experimental design based on the vaccine’s attributes. A total of 2450 samples from 31 provinces in Mainland China were collected to independently estimate the public’s WTP in these nine scenarios with logistic, normal, log-logistic and log-normal parameter models. Based on this estimation, several external scope tests were designed to verify the validity and reliability of the CV estimate results. Results In the 20 pairs of COVID-19 vaccine scenarios, 6 pairs of scenarios were classified as negative scope issues, therefore not passing the external scope test. Of the remaining 14 pairs of scenarios, only four pairs of scenarios completely passed the external scope test, and one pair of scenarios partially passed the external scope test. Significant negative scope and scope insensitivity issues were revealed. Conclusion In the context of a dynamic pandemic environment, the findings of this study reveal that the CV method may face difficulty in effectively estimating respondents’ WTP for the COVID-19 vaccine. We suggest that future studies be cautious in applying the CV method to estimate the public’s WTP for the COVID-19 vaccine.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-021-00706-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:20:y:2022:i:3:d:10.1007_s40258-021-00706-9

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-021-00706-9

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().